{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:59:23Z","timestamp":1789185563021,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cmi.2025.10.007","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:53:49Z","timestamp":1760694829000},"page":"230-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of tedizolid in the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1016","volume":"32","author":[{"given":"Patricia","family":"Sevilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altea","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"P\u00e9rez-Olaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Camarena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.10.007_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106637","article-title":"Skin infections in Europe: a retrospective study of incidence, patient characteristics and practice patterns","volume":"60","author":"Grossi","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.10.007_bib2","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/14787210.2021.1828865","article-title":"Acute bacterial skin and skin-structure infections, efficacy of Dalbavancin: a systematic review and meta-analysis","volume":"20","author":"Monteagudo-Mart\u00ednez","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cmi.2025.10.007_bib3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/QCO.0000000000001092","article-title":"The future approach for the management of acute bacterial skin and skin structure infections","volume":"38","author":"Tiseo","year":"2025","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.cmi.2025.10.007_bib4","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.jemermed.2024.03.003","article-title":"Single intravenous dose dalbavancin pathway for the treatment of acute bacterial skin and skin structure infections: considerations for emergency department implementation and cost savings","volume":"67","author":"LoVecchio","year":"2024","journal-title":"J Emerg Med"},{"key":"10.1016\/j.cmi.2025.10.007_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/ph13110333","article-title":"New antibiotics for the treatment of acute bacterial skin and soft tissue infections in pediatrics","volume":"13","author":"Principi","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cmi.2025.10.007_bib6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ajem.2024.10.040","article-title":"Use of lipoglycopeptides for moderate to severe ABSSSI in the emergency department","volume":"87","author":"Treu","year":"2025","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.cmi.2025.10.007_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2146\/ajhp130482","article-title":"Tedizolid: a new oxazolidinone antimicrobial","volume":"71","author":"Kisgen","year":"2014","journal-title":"Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm"},{"key":"10.1016\/j.cmi.2025.10.007_bib8","first-page":"866","article-title":"Efficacy and safety of antibiotics in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections: a systematic review and network meta-analysis","volume":"13","author":"Liu","year":"2024","journal-title":"Antibiot Basel Switz"},{"key":"10.1016\/j.cmi.2025.10.007_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40265-015-0352-7","article-title":"Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens","volume":"75","author":"Zhanel","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2025.10.007_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10096-020-04015-2","article-title":"Tedizolid: a service evaluation in a large UK teaching hospital","volume":"40","author":"York","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.10.007_bib11","first-page":"1237","article-title":"Study on the efficacy and safety of tedizolid in Japanese patients","volume":"13","author":"Ishikawa","year":"2024","journal-title":"Antibiot Basel Switz"},{"key":"10.1016\/j.cmi.2025.10.007_bib12","article-title":"Resistance mechanisms and tedizolid susceptibility in clinical isolates of linezolid-resistant bacteria in Japan","volume":"7","author":"Shoji","year":"2025","journal-title":"JAC-Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.10.007_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40262-021-01099-7","article-title":"Pharmacokinetics and pharmacodynamics of tedizolid","volume":"61","author":"Iqbal","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2025.10.007_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/CE.S187499","article-title":"Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy","volume":"14","author":"Bassetti","year":"2019","journal-title":"Core Evid"},{"key":"10.1016\/j.cmi.2025.10.007_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/17425255.2017.1290080","article-title":"Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections","volume":"13","author":"McBride","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.cmi.2025.10.007_bib16","first-page":"137","article-title":"Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis","volume":"8","author":"Lan","year":"2019","journal-title":"Antibiot Basel Switz"},{"key":"10.1016\/j.cmi.2025.10.007_bib17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.10.007_bib18","series-title":"Choosing effect measures and computing estimates of effect","first-page":"143","author":"Higgins","year":"2019"},{"key":"10.1016\/j.cmi.2025.10.007_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cmi.2025.10.007_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/INF.0000000000003010","article-title":"Safety and efficacy of oral and\/or intravenous tedizolid phosphate from a randomized phase 3 trial in adolescents with acute bacterial skin and skin structure infections","volume":"40","author":"Bradley","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2025.10.007_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02252-18","article-title":"Efficacy and safety of tedizolid phosphate versus linezolid in a randomized phase 3 trial in patients with acute bacterial skin and skin structure infection","volume":"63","author":"Lv","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.10.007_bib22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jiac.2018.01.010","article-title":"Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan\u2014results of a randomised, multicentre phase 3 study","volume":"24","author":"Mikamo","year":"2018","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.cmi.2025.10.007_bib23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/INF.0000000000004807","article-title":"A phase 3 study of the safety and efficacy of tedizolid phosphate in patients <12 years of age with acute bacterial skin and skin structure infections","volume":"44","author":"Mngqibisa","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2025.10.007_bib24","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","article-title":"Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial","volume":"14","author":"Moran","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.10.007_bib25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.10.007_bib26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/INF.0000000000003597","article-title":"Activity of tedizolid and comparator agents against gram-positive isolates causing skin and skin structure infections in pediatric patients in United States hospitals (2015-2019)","volume":"41","author":"Carvalhaes","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.cmi.2025.10.007_bib27","first-page":"900","article-title":"In vitro activities of ceftobiprole, dalbavancin, tedizolid and comparators against clinical isolates of methicillin-resistant Staphylococcus aureus associated with skin and soft tissue infections","volume":"12","author":"Maraki","year":"2023","journal-title":"Antibiot Basel Switz"},{"key":"10.1016\/j.cmi.2025.10.007_bib28","first-page":"507","article-title":"In vitro activity of tedizolid and other comparator drugs in methicillin-resistant Staphylococcus aureus isolates in skin and soft tissue infections in seven Colombian hospitals","volume":"38","author":"Leal","year":"2018","journal-title":"Biomed Rev Inst Nac Salud"},{"key":"10.1016\/j.cmi.2025.10.007_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bjid.2017.03.010","article-title":"In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid","volume":"21","author":"Vanegas M\u00fanera","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.cmi.2025.10.007_bib30","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Tedizolid: Rationale for EUCAST Clinical Breakpoints, Version 1.0; 2018. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Tedizolid_rationale_document_1.0_20180419.pdf"},{"key":"10.1016\/j.cmi.2025.10.007_bib31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s00134-025-07884-3","article-title":"Identification and validation of robust hospital-acquired pneumonia subphenotypes associated with all-cause mortality: a multi-cohort derivation and validation","volume":"51","author":"Martin","year":"2025","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2025.10.007_bib32","doi-asserted-by":"crossref","first-page":"e710","DOI":"10.1093\/cid\/ciab032","article-title":"A phase 3, randomized, double-blind study comparing tedizolid phosphate and linezolid for treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia","volume":"73","author":"Wunderink","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25005051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:49:57Z","timestamp":1768841397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25005051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1198743X25005051"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.10.007","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tedizolid in the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis of randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}